Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > high-throughput solutions for vaccine R&D based on ELISA

high-throughput solutions for vaccine R&D based on ELISA

Background

Vaccination is one of the most important and economic tools to protect the community from infectious diseases. There are about 60% of the population were fully vaccinated around the world, however, as the virus mutates continuously, the increasingly strong transmission and immune escape capabilities of the mutant strains have brought great challenges to the prevention and control of the epidemic. The emergence of many breakthrough infection cases represents that the "immune barrier" created by vaccination against the wild-type strain of COVID-19 may be flawed. Therefore we urgently need next-generation vaccines that still have high protective efficacy against mutant strains.

As the world experiences a new wave of outbreaks due to the emergence of the Omicron variant, vaccine manufacturers have already stepped up for the development of vaccines against new variants. Earlier, Moderna and Pfizer had announced to start the research on candidate vaccines against Delta and Omicron variants. In China, the China Center for Disease Control and Prevention, Sinovac and Sinopharm Group received the Omicron variant virus isolated by HKU and began their work. In addition, CanSino Bio said they were also working on the development of a new vaccine against the Omicron variant.

In order to support and regulate the development of COVID-19 vaccines, the Food and Drug Administration (FDA) issued the "Development and Licensure of Vaccines to Prevent COVID-19" to determine key indicators for monitoring the whole process of vaccine development.

>>> click to download the Development and Licensure of Vaccines to Prevent COVID-19

ACROBiosystems has undergone methodological validation and independently developed a series of COVID-19-related ELISA kits according to the application as described in the guidelines, aiming to provide comprehensive solutions ranging from quality control of vaccine production to preclinical and clinical research.

Advantages:
- For wild type and VOCs (Alpha, Beta, Gamma, Delta, Omicron) detection;
- Can detect antigens and antibodies (including neutralizing antibodies, total antibodies, IgG, IgM, IgG antibody subtypes, etc.);
- Cover species of Human, Mouse and Monkey, to meet the needs of preclinical and clinical research;
- Strict quality control to ensure that the batch-to-batch difference and precision < 10%;
- High throughput, can detect 90+ samples within 2 hours;
- Low environmental requirements, simple operation.
Manufacture and quality control

Antigen detection

Product list
Cat. No.Product DescriptionPreorder/Order
Assay Data

SARS-CoV-2 Spike RBD (B.1.1.529) Specific ELISA Kit (For Vaccine Development)(Cat. No. RAS-A082) can specifically detect SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) (Cat. No. SPD-C522e), and cannot detect the spike RBD of other strains, inchuding WT, Alpha, Beta, Gamma and Delta.

Preclinical research (Animal models)

Immunogenicity assay

Product list
LineageCat. No.Product DescriptionPreorder/Order
Assay Data

Cat. No. RAS-T045 can be used to detect the mouse IgG antibody titer, the titer value is 12800.

Clinical research

Neutralizing antibody titer detection

Product list
LineageCat. No.Product DescriptionPreorder/Order

>>>Click to find out more solution for neutralization assay: pseudovirus and related service

Assay Data

Anti-SARS-COV-2 Neutralizing Antibody Titer Serologic Assay Kit based on WT RBD (Cat. No. RAS-N022), B.1.1.7 RBD (Cat. No. RAS-N028), B.1.351 RBD (Cat. No. RAS-N031) and P.1 RBD (Cat. No. RAS-N034) are used to detect neutralizing antibodies in 56 post-vaccination serum samples in order to evaluate vaccine efficacy against SARS-CoV-2 Variants of Concerns (VOC).

IgG Antibody Titer Detection

Product list
LineageCat. No.Product DescriptionPreorder/Order

>>>Click to find out more ELISA kits for IgM/ Total antibody detection

Assay Data

Cat.No. RAS-T024 can accurately test the antibody titer in vaccinated serum. The batch-to-batch difference and precision were all less than 10%.

Anti-SARS-CoV-2 Antibody IgG Quantitative Detection Kit (Spike Trimer) (Cat.No. RAS-T048) is developed for quantitative detection of IgG antibodies in post-vaccination serum. This kit is an important supplement to the existing vaccine evaluation methods which significantly improve the efficiency and accuracy of vaccine evaluation.

ADE/VED study

Product list
LineageCat. No.Product DescriptionPreorder/Order

>>>Click to find out more ELISA kits for IgM/ Total antibody detection

Assay Data

cross-validation data for antibody subtype detection

>>> If you have any customized inquiries or suggestions for SARS-CoV-2 (COVID-19) related product development, please click here.

>>> Any custom requests, suggestions or feedback are welcome. click here.

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message